Clinical Trial Update: A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating varlilumab (anti-CD27) in combination with sunitinib for metastatic clear-cell renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• Varlilumab (varlilumab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Carcinoma, Renal Cell, Kidney Diseases | Phase 1 | Status: TERMINATED